Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors
12. November 2024 07:10 ET
|
Jeito Capital
Jeito Capital co-leads €164.5 million1 ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development ofAnti-Claudin-1 (CLDN1) ADCs in solid tumors ...
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
16. Juli 2024 05:10 ET
|
Jeito Capital
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing This new financing will support broad late-stage clinical development program for...
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
29. Mai 2024 07:02 ET
|
Jeito Capital
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress...
Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
07. September 2023 03:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 65 million (USD 711M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases Jeito Capital...
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma pour Noema Pharma, une biopharma ciblant les maladies graves du système nerveux central
07. März 2023 04:00 ET
|
Jeito Capital
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma ciblant les maladies graves du système...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
07. März 2023 04:00 ET
|
Jeito Capital
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central...
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
06. Dezember 2022 07:00 ET
|
Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
22. November 2022 05:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...
Jeito Capital investit dans CatalYm Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie
22. November 2022 05:00 ET
|
Jeito Capital
Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie Jeito Capital co-dirige un financement de série C de 50 millions d'euros avec Brandon...
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies auto-immunes
01. November 2022 09:05 ET
|
Jeito Capital
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies...